Register for our free email digests:
Threshold Pharmaceuticals Inc.
Division of Molecular Templates Inc.
www.thresholdpharm.com
Latest From Threshold Pharmaceuticals Inc.
Deals Shaping The Medical Industry, July 2017
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2017.
Pipeline Watch: Phase III Progress With Anacetrapib, ALKS 3831 And LentiGlobin
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Deal Watch: Success Nets CytomX Another $200m From BMS, Up To $3.6bn For Milestones
Bristol-Myers Squibb expanded its collaboration with CytomX for $200m up front and up to $3.6bn in milestone fees. Also, Takeda spun out eight non-core molecules into a new joint venture and X-Chem executed two deals with Japanese partners, among other recent deals.
Company Information
- Industry
- Biotechnology
-
Medical Devices
- Diagnostic Imaging Equipment & Supplies
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
- Therapeutic Areas
- Cancer
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Molecular Templates Inc.
- Senior Management
-
Barry Selick, PhD, CEO
Eric Malek, SVP, Corp. Dev.
Tillman Pearce, MD, CMO
Joel A Fernandes, SVP, Fin. - Contact Info
-
Threshold Pharmaceuticals Inc.
Phone: (650) 474-8200
170 Harbor Way
Ste. 300
South San Francisco, CA 94080
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice